One-Pass clot removal device tested in major stroke study
NCT ID NCT04562194
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a device called the NeVa stent retriever to see how well it can remove blood clots in people having a severe stroke. The goal is to restore blood flow to the brain in a single pass. The study will enroll 600 adults who are already scheduled to have this procedure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 600 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2020
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Only subjects already treated with the NeVa thrombectomy devices can be considered for enrollment. 1. Age ≥18 2. NIHSS score ≥ 6 3. Pre-stroke mRS score ≤ 1 4. Intracranial arterial occlusion of the distal intracranial carotid artery or middle cerebral artery (M1/M2), anterior cerebral artery (ACA), posterior cerebral artery (PCA), basilar artery, or vertebral artery demonstrated with DSA. 5. Thrombectomy procedure can be initiated within 24 hours from symptom onset (defined as time last known well \[TLKW\]) 6. Imaging Inclusion Criteria: The patient should have confirmed LVO and salvageable penumbra. Any automated software for determine the volume of viable tissue is acceptable. patient selection should follow the following guidelines: * ASPECTS 6-10 if treatment started 0-6 hours from TLKW * ASPECTS 8-10 if treatment started 6-24 hours from TLKW * Ischemic core ≤ 50 cc 7. Subject or legal representative is able and willing to give informed consent within 72 hours after the intervention (may use independent physician consent in this timeframe and gain subject or legal representative consent later than 72 hours). Exclusion Criteria: 1. Pre-existing medical neurological or psychiatric disease that would confound the neurological or functional evaluations, e.g. dementia with prescribed anti-cholinesterase inhibitor (e.g. Aricept). 2. Cardiopulmonary resuscitation, significant cardiac arrhythmia, evidence of ongoing myocardial infarction, concern for pre- treatment pulmonary aspiration. 3. Clinical symptoms suggestive of bilateral stroke or stroke in multiple territories 4. Cerebral vasculitis 5. History of severe allergy to contrast medium. 6. Known allergy to NeVa materials (nitinol, stainless steel) 7. Suspicion of aortic dissection, septic embolus, or bacterial endocarditis 8. Systemic infection 9. Significant mass effect with midline shift 10. Evidence of intracranial tumor (except small meningioma) 11. Inability to deploy NeVA device for at least one pass for any other reason 12. Life expectancy less than 6 months 13. Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the subject if an endovascular procedure was performed.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute ischemic stroke are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites in 3 countries. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Cleveland Clinic Abu Dhabi
RECRUITINGAbu Dhabi, United Arab Emirates
-
Hospital Espanol de Mendoza
RECRUITINGMendoza, Argentina
-
Niguarda Hospital
RECRUITINGMilan, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can PET scans reveal hidden heart inflammation after a stroke?
- Can an implanted heart monitor catch hidden irregular heartbeats after stroke?
- China builds national watchdog for brain blood vessel devices
- Can tiny neural exosomes help the brain heal after a severe stroke?
- Can a new antibody boost recovery after severe stroke?
- After stroke, a balloon or a stent? trial tests which rescue opens blocked brain arteries better